Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer-Reference-Cited by-同舟云学术

Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer

Published:2023-01 Issue:1 Volume:122 Page:4-8
ISSN:0929-6646
Container-title:Journal of the Formosan Medical Association
language:en
Short-container-title:Journal of the Formosan Medical Association

Author:

Kuo Hung-Yang,Guo Jhe-Cyuan,Hsu Chih-Hung

Funder

Ministry of Health and Welfare

Publisher

Elsevier BV

Subject

General Medicine

Reference7 articles.

1. Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: a long-awaited breakthrough finally arrives;Kuo;J Formos Med Assoc,2020

2. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study;Sun;Lancet,2021

3. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma;Doki;N Engl J Med,2022

4. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial;Luo;JAMA,2021

5. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the phase III ORIENT-15 study;Shen;Ann Oncol,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial;2024-01-12

2. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): A Multi-center Prospective Randomized Clinical Trial;2023-07-26

3. Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer;Thoracic Cancer;2023-06-20

4. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis;Chemotherapy;2023